To: drkaz who wrote (4540 ) 4/20/2015 11:53:24 AM From: Kirk © 1 RecommendationRecommended By
Respond to I wonder how long it takes for that story to show up on the homepage for the company? http://www.prnewswire.com/news-releases/nanoviricides-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model-300068316.html SHELTON, Conn., April 20, 2015 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the laboratory of Dr. Ken S. Rosenthal at Northeast Ohio Medical University where Dr. Rosenthal is now Professor Emeritus. He is a leading researcher in herpes virus anti-viral agents and vaccines. Two of the anti-Herpes nanoviricides® reduced the extent of disease (morbidity) and mortality of the HSV-1 infected animals that were treated. These nanoviricides also reduced virus production in cell culture. Importantly, topical dermal treatment with these nanoviricides led to almost complete (>85%) survival of the infected mice in this animal model whereas all untreated animals died of the disease. Further, these nanoviricides were superior to topical treatment with an acyclovir formulation employed as a positive control. "Our broad-spectrum anti-herpes drug development program is now producing dramatic results in animal models," said Dr. Eugene Seymour, MD, MPH, CEO of the Company, adding, "Our drug candidates had previously exhibited greater than 99.9% viral load reduction in cell cultures. With the marked success in animal effectiveness, we believe that we will be able to declare a drug candidate against herpes viruses after certain additional testing."
